Fleming Fund investment expanded antimicrobial resistance surveillance where the need was greatest
Antimicrobial resistance is no longer a future threat in low- and middle-income countries; it is already shaping everyday clinical decisions, often in settings where microbiology services are thin, delayed, or absent. The Fleming Fund, launched by the UK Government in 2015, was designed to change that reality by strengthening surveillance across Africa and Asia through a One Health model that linked human, animal, and environmental health data streams. This article draws on program experience, country implementation evidence, and published literature to assess how that effort was translated into operational surveillance capacity, and whether the investments produced data that could actually be used.
The answer is encouraging, but not simple.
Across supported countries, the program built surveillance from the ground up. Investment flowed into laboratory infrastructure, workforce development, quality assurance, data systems, governance, and data use. Those are not abstract program inputs; they are the basic scaffolding required for a reliable antibiogram, for tracking shifting resistance patterns, and for giving clinicians more than guesswork when first-line therapy fails. In practical terms, these investments enabled substantial growth in routine bacteriology and antimicrobial susceptibility testing, strengthened reference and surveillance laboratory capacity, and increased participation in external quality assessment. Reporting to the World Health Organization’s Global Antimicrobial Resistance and Use Surveillance System also expanded, which matters because data that never leave a local lab cannot inform national policy or regional comparisons.
Surveillance capacity rose, but the system had to absorb multiple weak links at once
The program did not rely on a single intervention because surveillance failure rarely has a single cause. Better equipment does little when reagents run out. Training cannot fully compensate for staff turnover. Digital platforms lose value when they are disconnected from clinical workflows. The Fleming Fund therefore paired physical and technical investment with governance structures and data-use pathways, aiming to create surveillance systems that could generate data, move it, and interpret it without collapsing at one vulnerable point.
In many settings, that approach appears to have worked. Routine bacteriology and susceptibility testing increased, and the network of reference and surveillance laboratories became stronger. Participation in external quality assessment rose as well, which is especially important in antimicrobial resistance work because the credibility of a resistance map depends on whether the underlying susceptibility results are reproducible across sites. A surveillance system that cannot pass quality checks may still produce numbers, but those numbers will be too unstable to guide treatment policy or stewardship.
Complementary data streams broadened the view of resistance pressure
The program also supported surveillance beyond conventional bacterial culture and susceptibility testing. Antimicrobial use and consumption data were incorporated, and in some settings the initiative extended into burden-of-disease and genomic surveillance. That broader picture is clinically important. Resistance patterns do not emerge in isolation; they are driven by prescribing pressure, access to diagnostics, transmission dynamics, and local epidemiology. Consumption data help explain why resistance rises in one region and remains lower in another. Genomic surveillance can reveal whether a resistant strain is spreading clonally or appearing through repeated selection pressure. Burden-of-disease data connect laboratory findings to clinical consequences, helping policymakers decide which pathogens deserve urgent attention.
These layers make surveillance more actionable, not merely more detailed. A narrow laboratory dataset can tell a clinician that resistance is rising. A connected system can show whether the problem is concentrated in hospitals, community settings, or a particular pathogen cluster, and whether procurement, stewardship, or infection prevention is the most rational response.
Fragility remains a structural barrier to durable progress
Progress was uneven. The report identifies a familiar but stubborn list of constraints: fragile infrastructure, procurement and supply chain bottlenecks, workforce turnover, fragmented data systems, weak clinical-laboratory interfaces, limited representativeness, and uncertain long-term financing. Each of these can erode surveillance in a different way, but together they create a pattern that is easy to recognize in many LMIC health systems. A lab may be upgraded, yet remain dependent on imports for reagents. A data platform may be installed, yet not communicate with hospital records. A trained workforce may be assembled, yet disperse before institutional memory is established.
The clinical consequence is immediate. If culture results arrive too late, or not at all, empiric therapy stays broad even when resistance data suggest it should narrow. If surveillance sites are not representative, national policy can overestimate or underestimate the true burden. If clinicians do not trust laboratory output, the data remain trapped in spreadsheets rather than shaping prescribing habits or stewardship campaigns.
The main lesson is operational, not theoretical
The Fleming Fund experience shows that strengthening AMR surveillance in LMICs is feasible when investment is sustained and system-wide. The critical point is that surveillance is not just a laboratory problem. It is a chain of dependent functions, from specimen collection and testing to reporting, interpretation, and clinical action. Break any one of those links and the value of the entire enterprise falls quickly.
For future surveillance strategies, the article points toward a more integrated model. Clinical care needs to sit closer to laboratory data. Digital and analytical capacity need to improve so that data are not only collected but interrogated in real time. Diagnostic access must broaden so that surveillance reflects more than a few urban referral centers. Domestic financing is essential if gains are to survive beyond donor support. Without that transition, surveillance can expand for a few years and then contract once external funding shifts.
Financing and integration will determine whether the gains last
The most durable contribution of the Fleming Fund may be that it demonstrates what effective antimicrobial resistance surveillance actually requires in resource-limited settings. It is not enough to count isolates or install software. High-quality surveillance depends on public health infrastructure, procurement reliability, laboratory competence, governance, and a clinical culture willing to use the data once they arrive. The report makes clear that these components can be assembled, but also that they remain vulnerable to the same pressures that weaken many health systems: unstable supply chains, thin staffing, and uncertain budgets.
For clinicians and policymakers, the implication is straightforward. If the goal is to generate surveillance data that change prescribing, policy, and prevention, the investment has to extend beyond the laboratory bench and into the systems that keep the bench functioning. The unresolved challenge is whether countries can convert donor-supported surveillance gains into domestically financed platforms that continue to produce representative, quality-assured data after external funding recedes.